A new AI tool, BIOPREVENT, predicts serious post-transplant complications months before symptoms appear using blood biomarkers and clinical data.
Key Details
- 1BIOPREVENT was developed by MUSC Hollings Cancer Center and validated with data from 1,310 transplant recipients.
- 2The tool outperformed standard clinical models in predicting chronic graft-versus-host disease (GVHD) and transplant-related death.
- 3BIOPREVENT uses seven immune protein biomarkers and nine clinical factors to assess risk.
- 4Predictions were validated in an independent patient cohort, showing reliable risk stratification up to 18 months post-transplant.
- 5A free, web-based application is available for clinicians to use the tool for research and risk assessment.
Why It Matters
Early identification of high-risk transplant patients can enable closer monitoring and potential intervention before severe complications arise, representing a significant advance in personalized medicine using AI and biomarker data. This AI tool sets a precedent for broader use of machine learning models to improve outcomes in complex medical scenarios requiring longitudinal risk prediction.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.